Stay updated on Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial
Sign up to get notified when there's something new on the Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial page.

Latest updates to the Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial page
- Check5 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4, indicating a minor site update with no changes to study data or history details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page history shows an addition of Revision: v3.3.3 and deletions of HHS Vulnerability Disclosure and Revision: v3.3.2, indicating administrative updates to the site’s footer and history entries. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision label in the site footer updated from v3.2.0 to v3.3.2. No changes to study data, layouts, or navigation were observed.SummaryDifference0.1%

- Check63 days agoChange DetectedThe government funding and operating status notice was removed from the page; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedThe new screenshot shows a visual refresh of the Record History page with the same version entries and layout as the old screenshot. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check106 days agoChange Detected- Added a government funding status notice and operating details for the NIH Clinical Center, indicating possible delays and updated status references. - Updated software version from v3.1.0 to v3.2.0.SummaryDifference9%

Stay in the know with updates to Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial page.